FDA supplemental approval: Buprenorphine Hydrochloride (REMS)

AI Summary

This is an FDA supplemental approval action granting REMS (Risk Evaluation and Mitigation Strategy) status to buprenorphine hydrochloride sublingual tablets (2 mg and 8 mg base formulations) submitted by Barr Pharmaceuticals. The record documents regulatory authorization only and does not contain clinical trial results, efficacy data, or comparative safety information.

Plain-language summary

FDA supplemental approval action establishing Risk Evaluation and Mitigation Strategy (REMS) requirements for buprenorphine hydrochloride sublingual tablets; does not report clinical trial outcomes.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory action establishes mandatory REMS requirements for the dispensing and use of these buprenorphine formulations; clinicians should consult the approved REMS program details for prescribing, dispensing, and monitoring requirements.

Caveats

• Record contains no clinical trial data, efficacy outcomes, or safety study results
• REMS program details not specified in this record; refer to full REMS document for requirements
• No comparative efficacy or safety information provided relative to other buprenorphine formulations or opioid-use-disorder treatments
• Approval status and date confirm regulatory action but do not indicate scope or rationale for REMS requirement

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.